Clinical trial Recruiting at 8 sites Phase 3 Interventional Ages 18 to 45 Women only

Comparing IV and oral iron treatments for anemia in pregnant women

Official title: Double-blind Placebo-controlled Multicenter Randomized Trial of Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

Run by Women and Infants Hospital of Rhode Island · NCT05462704 · Data updated 2026-11-12

This study is testing whether intravenous iron or oral iron supplements work better for pregnant women with anemia to improve their health and their baby's development.

More Pregnancy trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 45 Years
SexWomen only
Enrollment300 (estimated)
SponsorWomen and Infants Hospital of Rhode Island
Academic / other
Locations8 sites (Birmingham, Alabama and 7 other locations)
StatusRecruiting
StartedJanuary 17, 2023
Main results expectedMarch 30, 2027
Study endsMarch 31, 2027
Registry record updatedJune 10, 2025
Trial IDNCT05462704 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are pregnant women aged 18-45 with singleton gestation and diagnosed with moderate-to-severe iron-deficiency anemia.

Probably not a fit

Patients with non-iron-deficiency anemia or those with conditions that affect iron absorption may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is a double-blind, placebo-controlled, multicenter randomized trial involving 746 pregnant women in the U.S. who have moderate-to-severe iron-deficiency anemia. The study aims to compare the effectiveness, safety, and cost-effectiveness of intravenous iron versus oral iron supplementation in reducing severe maternal morbidity and improving offspring neurodevelopment. Participants will be monitored for outcomes such as the need for blood transfusions and the health of their newborns. The trial specifically targets women between 13 to 30 weeks of gestation with low hemoglobin and ferritin levels.

Why it matters

Potential benefit: If successful, this study could provide a more effective treatment option for iron-deficiency anemia in pregnant women, potentially reducing complications for both mothers and their babies.

How similar studies have gone: Previous studies have indicated that intravenous iron can be effective in treating iron-deficiency anemia, but this specific comparison in a pregnant population is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Pregnant women between the ages of 18-45
* Singleton gestation
* Iron-deficiency anemia (serum ferritin \<30ng/mL and Hb\<11 g/dL)
* At 13-30 weeks gestation
* Plan to deliver at participating hospital

Exclusion Criteria:

* Non-iron-deficiency anemia e.g thalassemia, sickle cell disease, B12 or folate deficiency, hypersplenism.
* Malabsorptive syndrome, inflammatory bowel disease, gastric bypass, or sensitivity to oral or IV iron
* Multiple gestation
* Inability or unwillingness to provide informed consent
* Inability to communicate with members of the study team, despite the presence of an interpreter
* Planned delivery at a non-study affiliated hospital

Where it's running

  • University of Alabama Medical Center
    Birmingham, Alabama, United States
    Recruiting
  • GNP Research at Heme-on-Call
    Miami, Florida, United States
    Recruiting
  • Michigan University Medical Center
    Ann Arbor, Michigan, United States
    Recruiting
  • Washington University Medical Center
    St Louis, Missouri, United States
    Recruiting
  • Oregon Health and Sciences Uiversity Medical Center
    Portland, Oregon, United States
    Recruiting
  • Hasbro Children's Hospital
    Providence, Rhode Island, United States
    Recruiting
Show 2 more locations
  • Women & Infants Hospital of Rhode Island
    Providence, Rhode Island, United States
    Recruiting
  • University of Utah Hospital
    Salt Lake City, Utah, United States
    Recruiting

Study contacts

  • Principal investigator: Methodius Tuuli, MD, MPH, MBA — Women and Infants Hospital of Rhode Island
  • Study coordinator: Crystal Ware, BSN, CCRP
  • Email: cware@wihri.org
  • Phone: 401-274-1122

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.